Skip to main content

Collections open for submissions

Latest updates from major conferences

This Journal of Hematology & Oncology and Experimental Hematology & Oncology series intends to publish Correspondences with latest updates on novel agents and regimens from major conferences on blood and cancer disorders. Each Correspondence serves as a summary and analysis of 5 or more abstracts on a similar focus from a major international conference. 

First-ever clinical trials

This series calls for clinical studies on novel agents for cancers and blood disorders. Summaries and reviews on first-in-human or first-in-class studies are also welcome.
 

New developments in delivery technology, materials, and molecular engineering for drug discovery

This series covers new technology, materials, and models for drug discovery. Development and applications of organoids, 3D cultures, PDX modes, nano-molecules, AI technology, and single-cell maps for drug discovery will be the focus. 

Aims and scope

Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology. Read more.

Articles

Cancer Awareness Month Collections

In recognition of Lung, Pancreatic, and Gastric Cancer Awareness Months in November, Editors from across our OA oncology journals have chosen compilations of articles to highlight the latest advances in research for these cancer types.

© Mopic / stock.adobe.com

Experimental Hematology & Oncology

Submit your research to our companion journal, Experimental Hematology & Oncology.

CAHON: Stop hate crimes and racism

The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. We are proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond. 

Editor's quote

"Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists."

Prof Delong Liu, Editor-in-Chief, Journal of Hematology & Oncology

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2022 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    74 days submission to accept (Median)

    2022 Usage 
    2,836,875 downloads
    9,883 Altmetric mentions 

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here